Trial Profile
A Phase 1/2 Study of Deep IL-15 Loaded T-Cells Alone and in Combination With Pembrolizumab in Patients With Select Solid Tumors and Lymphomas
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; RPTR 147 1 (Primary) ; RPTR 147 2 (Primary)
- Indications Head and neck cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Repertoire Immune Medicines
- 02 Dec 2022 Status changed from active, no longer recruiting to discontinued.
- 30 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 04 May 2022 Planned End Date changed from 8 Feb 2023 to 9 Jul 2026.